Search

Displaying results 8501 - 8510 of 10000 in total
  1. Drug

    RAP-103

    go.drugbank.com/drugs/DB28444
    Experimental

    RAP-103 is a multi-chemokine receptor antagonist which is orally active.[A274606, A274611]

  2. Drug

    Alcestobart

    go.drugbank.com/drugs/DB28487
    Investigational

    Alcestobart is a biologic drug. … Alcestobart is under investigation in clinical trial NCT05909904 (A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma).

  3. Drug

    Efimosfermin alfa

    go.drugbank.com/drugs/DB28564
    Investigational

    Efimosfermin Alfa is a biologic drug. … Efimosfermin Alfa is under investigation in clinical trial NCT07221188 (A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected

  4. Drug

    VIR-5500

    go.drugbank.com/drugs/DB28578
    Investigational

    VIR-5500 is a small molecule drug. VIR-5500 is under investigation in clinical trial NCT05997615 (Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer).

  5. Drug

    VIR-5818

    go.drugbank.com/drugs/DB28582
    Investigational

    VIR-5818 is a biologic drug.

  6. Drug

    Adermastat

    go.drugbank.com/drugs/DB28906
    Investigational

    Adermastat is a small molecule drug.

  7. Drug

    Acellular nerve allograft

    go.drugbank.com/drugs/DB30293
    ApprovedInvestigational

    Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral

  8. Drug

    MVR-C5252

    go.drugbank.com/drugs/DB30379
    Investigational

    MVR-C5252 is a biologic drug. MVR-C5252 is under investigation in clinical trial NCT06126744 (Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252).

  9. Drug

    CX-051869

    go.drugbank.com/drugs/DB31656
    Approved

    CX-051869 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage LP.8.1.

  10. Drug

    FRAX716

    go.drugbank.com/drugs/DB31795
    Experimental

    FRAX716 is a group I-specific p21-activated kinase (PAK) inhibitor which dramatically inhibits the phosphorylation of PAK and Mek1.[A274678]